Combination Therapy of BCR-ABL-Positive B Cell Acute Lymphoblastic Leukemia by Tyrosine Kinase Inhibitor Dasatinib and c-JUN N-Terminal Kinase Inhibition

Journal of Hematology & Oncology
19 Jun, 2020 ,

Xinhua Xiao conducted a studied effect of JNK inhibition with or without BCR-ABL  Tyrosine Kinase Inhibitor dasatinib on BCR-ABL+ B-Acute Lymphoblastic Leukemia  cells was analyzed by the CellTiter-Glo® Luminescent Cell Viability Assay. The researchers concluded that simultaneously targeting both BCR-ABL and JNK kinase might serve as a promising therapeutic strategy for Ph+ B-ALL.